{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:46:30Z","timestamp":1766515590472,"version":"3.40.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10787-025-01658-5","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T10:54:05Z","timestamp":1739616845000},"page":"1033-1042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6678-7349","authenticated-orcid":false,"given":"Mable","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3595-8903","authenticated-orcid":false,"given":"Ancy Jenil","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7091-1268","authenticated-orcid":false,"given":"Karthik","family":"Chintharala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8714-2962","authenticated-orcid":false,"given":"Ana Carolina Putini","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8727-0522","authenticated-orcid":false,"given":"Ana Carolina Ventura","family":"de Santana de Jesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-5417","authenticated-orcid":false,"given":"Pawe\u0142","family":"\u0141ajczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-9263","authenticated-orcid":false,"given":"Khaled","family":"Alhwaishel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6347-1304","authenticated-orcid":false,"given":"Mario Saul Lira","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8924-9171","authenticated-orcid":false,"given":"Elizabet Taylor Pimenta","family":"Weba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"1658_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2294","author":"M Aslam","year":"2024","unstructured":"Aslam M, Ali MH, Irfan H (2024) Mirikizumab: a promising breakthrough in Crohn\u2019s disease treatment. Health Sci Rep. https:\/\/doi.org\/10.1002\/hsr2.2294","journal-title":"Health Sci Rep"},{"issue":"6","key":"1658_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","volume":"23","author":"HA Blair","year":"2021","unstructured":"Blair HA (2021) Secukinumab: A review in moderate to severe pediatric plaque psoriasis. Paediatr Drugs 23(6):601\u2013608. https:\/\/doi.org\/10.1007\/s40272-021-00476-w","journal-title":"Paediatr Drugs"},{"issue":"6","key":"1658_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamadermatol.2020.0188","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp KA, Tyring SK et al (2020) Efficacy and safety of risankizumab versus secukinumab in moderate-to-severe psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 156(6):643\u2013651. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0188","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1658_CR4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.21743","volume":"187","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Kimball AB, Augustin M et al (2022) Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol 187(6):866\u2013877. https:\/\/doi.org\/10.1111\/bjd.21743","journal-title":"Br J Dermatol"},{"key":"1658_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621956","volume":"12","author":"H Bugaut","year":"2021","unstructured":"Bugaut H, Aractingi S (2021) Major role of the IL-17\/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol 12:621956. https:\/\/doi.org\/10.3389\/fimmu.2021.621956","journal-title":"Front Immunol"},{"issue":"10","key":"1658_CR6","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L et al (2017) The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 31(10):1616\u20131626. https:\/\/doi.org\/10.1111\/jdv.14433","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1658_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/1744666X.2019.1610374","volume":"15","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Strober BE (2019) Mirikizumab and its role in the management of psoriasis: an overview. Expert Rev Clin Immunol 15(6):635\u2013644. https:\/\/doi.org\/10.1080\/1744666X.2019.1610374","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 3","key":"1658_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3310\/hta13suppl3\/10","volume":"13","author":"E Gospodarevskaya","year":"2009","unstructured":"Gospodarevskaya E, Picot J, Cooper K et al (2009) Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess 13(Suppl 3):61\u201366. https:\/\/doi.org\/10.3310\/hta13suppl3\/10","journal-title":"Health Technol Assess"},{"issue":"4","key":"1658_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80(4):913\u2013921","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1658_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jaad.2019.10.017","volume":"82","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Papp KA, Menter A et al (2020) Long-term efficacy and safety of tildrakizumab in moderate-to-severe plaque psoriasis: results from the Phase 3 reSURFACE 1 and reSURFACE 2 trials. J Am Acad Dermatol 82(4):935\u2013946. https:\/\/doi.org\/10.1016\/j.jaad.2019.10.017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1658_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaad.2015.12.032","volume":"74","author":"WW Huang","year":"2016","unstructured":"Huang WW, Feldman SR (2016) The cost of applying to dermatology residency. J Am Acad Dermatol 74(4):775\u2013776","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1658_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/09546634.2019.1617490","volume":"30","author":"AB Kimball","year":"2019","unstructured":"Kimball AB, Papp KA, Menter A et al (2019) The efficacy and safety of tildrakizumab in moderate-to-severe plaque psoriasis: results from the Phase 3 reSURFACE trials. J Dermatolog Treat 30(6):534\u2013540. https:\/\/doi.org\/10.1080\/09546634.2019.1617490","journal-title":"J Dermatolog Treat"},{"issue":"17","key":"1658_CR13","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","volume":"24","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Kim M (2023) Challenges and future trends in the treatment of psoriasis. Int J Mol Sci 24(17):13313. https:\/\/doi.org\/10.3390\/ijms241713313","journal-title":"Int J Mol Sci"},{"key":"1658_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/phar.4611","author":"P Mo\u0107ko","year":"2024","unstructured":"Mo\u0107ko P, Koperny M, \u015aladowska K et al (2024) Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: a systematic review and network meta-analysis. Pharmacotherapy Published Online September. https:\/\/doi.org\/10.1002\/phar.4611","journal-title":"Pharmacotherapy. Published Online September"},{"issue":"9","key":"1658_CR15","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","volume":"5","author":"K Papp","year":"2023","unstructured":"Papp K, Warren RB, Green L et al (2023) Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Lancet Rheumatol 5(9):e542\u2013e552. https:\/\/doi.org\/10.1016\/S2665-9913(23)00120-0","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"1658_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE et al (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2):377\u2013385","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1658_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Rich P, Maari C et al (2019) Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol 181(1):88\u201395. https:\/\/doi.org\/10.1111\/bjd.17628","journal-title":"Br J Dermatol"},{"issue":"3","key":"1658_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jaad.2019.08.058","volume":"82","author":"K Reich","year":"2020","unstructured":"Reich K, Burden AD, Kimball AB et al (2020a) Risankizumab versus secukinumab in moderate-to-severe plaque psoriasis: results from IMMerge trial. J Am Acad Dermatol 82(3):576\u2013583. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.058","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1658_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/09546634.2019.1598892","volume":"31","author":"K Reich","year":"2020","unstructured":"Reich K, Gooderham M, Menter A (2020b) Efficacy of mirikizumab in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Dermatol Treat 31(2):99\u2013107. https:\/\/doi.org\/10.1080\/09546634.2019.1598892","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1658_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR et al (2020) Efficacy and safety of mirikizumab in a randomized Phase 2 study of patients with ulcerative colitis. Gastroenterology 158(3):537-549.e10. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.043","journal-title":"Gastroenterology"},{"issue":"2","key":"1658_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1053\/j.gastro.2020.09.009","volume":"160","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Rubin DT, Ferrante M et al (2021) Mirikizumab in patients with ulcerative colitis: a phase 2, randomized, double-blind, placebo-controlled study. Gastroenterology 160(2):437-448.e13. https:\/\/doi.org\/10.1053\/j.gastro.2020.09.009","journal-title":"Gastroenterology"},{"issue":"4","key":"1658_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J et al (2021) Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol 22(4):425\u2013442. https:\/\/doi.org\/10.1007\/s40257-021-00603-w","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1658_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE (2021) Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 22(2):173\u2013192. https:\/\/doi.org\/10.1007\/s40257-020-00578-0","journal-title":"Am J Clin Dermatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01658-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01658-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01658-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:15:00Z","timestamp":1742303700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01658-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01658-5","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"type":"print","value":"0925-4692"},{"type":"electronic","value":"1568-5608"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}